Deborah Anne Forst
Deborah Anne Forst has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth R. Gerstner
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital , Charlestown, Massachusetts
12 shared publications - Jorg Dietrich
Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Boston, Massachusetts, United States
12 shared publications - Eudocia Quant Lee
Department of Neuro-Oncology, Dana-Farber Cancer Institute , Boston, MA
10 shared publications - Isabel Arrillaga-Romany
Neuro-oncology, Massachusetts General Hospital, Boston
10 shared publications - Tracy T. Batchelor
Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
10 shared publications - David A. Reardon
Harvard Medical School , Boston, Massachusetts
9 shared publications
Latest Publications
- 16 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Prognostic significance of contrast enhancement in newly diagnosed grade 2 IDH-mutant glioma
Background: Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 isocitrate dehydrogenase (IDH)-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with preoperative enhancement in this population. Methods: We retrospectively evaluated consecutive patients with grade 2 IDH-mutant glioma treated at 2 institutions between 2010 and 2021. Preoperative MRIs were assessed for intratumoral enhancement by 2 independent readers with third-reader adjudication. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier analysis and univariate and multivariable Cox regression. Results: Among 325 evaluable patients, the median age was 37 years, 47% had 1p/19q-codeletion, and 35% had gross total resection. Median follow-up was 10.5 years. Preoperative enhancement was observed in 53 (16%) patients, most commonly nonmeasurable (72%) or ill-defined (62%); most (87%) had no residual postoperative enhancement. Preoperative enhancement was not associated with OS or PFS in either univariate analyses (OS hazard ratio [HR] 1.16 [0.67-2.01], P = .591; PFS HR 1.25 [0.88-1.80], P = .216) or multivariable analyses adjusting for established prognostic factors (OS HR 0.86 [0.46-1.61], P = .633; PFS HR 1.29 [0.86-1.92], P = .219). Enhancement characteristics (measurable size, well-defined morphology) were not associated with OS. Conclusions: In grade 2 IDH-mutant glioma, preoperative enhancement was not associated with OS or PFS. These findings suggest that preoperative enhancement does not identify a higher-risk subgroup in this population and that its presence alone should not preclude consideration of vorasidenib in eligible patients.
- 16 October 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Prognostic significance of contrast enhancement in newly diagnosed grade 2 IDH-mutant glioma
Background: Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 isocitrate dehydrogenase (IDH)-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with preoperative enhancement in this population. Methods: We retrospectively evaluated consecutive patients with grade 2 IDH-mutant glioma treated at 2 institutions between 2010 and 2021. Preoperative MRIs were assessed for intratumoral enhancement by 2 independent readers with third-reader adjudication. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier analysis and univariate and multivariable Cox regression. Results: Among 325 evaluable patients, the median age was 37 years, 47% had 1p/19q-codeletion, and 35% had gross total resection. Median follow-up was 10.5 years. Preoperative enhancement was observed in 53 (16%) patients, most commonly nonmeasurable (72%) or ill-defined (62%); most (87%) had no residual postoperative enhancement. Preoperative enhancement was not associated with OS or PFS in either univariate analyses (OS hazard ratio [HR] 1.16 [0.67-2.01], P = .591; PFS HR 1.25 [0.88-1.80], P = .216) or multivariable analyses adjusting for established prognostic factors (OS HR 0.86 [0.46-1.61], P = .633; PFS HR 1.29 [0.86-1.92], P = .219). Enhancement characteristics (measurable size, well-defined morphology) were not associated with OS. Conclusions: In grade 2 IDH-mutant glioma, preoperative enhancement was not associated with OS or PFS. These findings suggest that preoperative enhancement does not identify a higher-risk subgroup in this population and that its presence alone should not preclude consideration of vorasidenib in eligible patients.
- Open Access
- 7 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
“Am I ever going to find myself again?”: Identity destabilization in patients with isocitrate dehydrogenase-mutant gliomas
Background: Patients with isocitrate dehydrogenase (IDH)-mutant gliomas often experience prolonged survival but frequently have persistent psychological distress and impaired quality of life (QOL). While prior research has characterized symptomatology and functional outcomes, less is known about how factors such as age and developmental stage shape distress and coping in this population. Our study sought to better understand these psychosocial dimensions of living with an IDH-mutant glioma, to inform the design of tailored supportive care. Methods: We conducted semistructured interviews with adults aged 18-65 years diagnosed with IDH-mutant gliomas (n = 20) receiving care at a large academic medical center. We used stratified purposeful sampling to ensure variation in age. Our multidisciplinary team coded and analyzed interview transcripts using reflexive thematic analysis. Results: Participants’ experiences coalesced around a central concept of destabilized identity, reflected in 5 interrelated themes: (1) yearning for an idealized past self; (2) shifting social roles; (3) existential uncertainty; (4) informational uncertainty; and (5) diverse emotional responses to identity conflict. Participants reported a loss of continuity with their premorbid selves, uncertainty about the future, and worries about sustaining cognitive and social functioning. This identity disruption was particularly distressing for younger adults navigating careers, relationships, and long-term life planning. Many expressed unmet support needs despite ongoing oncologic care. Conclusions: Disruption of personal identity emerged as a central feature of the experience of living with an IDH-mutant glioma. Supportive care that acknowledges and helps patients adapt to changes in their sense of self may improve overall psychosocial well-being and QOL.
- 7 August 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Open Access“Am I ever going to find myself again?”: Identity destabilization in patients with isocitrate dehydrogenase-mutant gliomas
Background: Patients with isocitrate dehydrogenase (IDH)-mutant gliomas often experience prolonged survival but frequently have persistent psychological distress and impaired quality of life (QOL). While prior research has characterized symptomatology and functional outcomes, less is known about how factors such as age and developmental stage shape distress and coping in this population. Our study sought to better understand these psychosocial dimensions of living with an IDH-mutant glioma, to inform the design of tailored supportive care. Methods: We conducted semistructured interviews with adults aged 18-65 years diagnosed with IDH-mutant gliomas (n = 20) receiving care at a large academic medical center. We used stratified purposeful sampling to ensure variation in age. Our multidisciplinary team coded and analyzed interview transcripts using reflexive thematic analysis. Results: Participants’ experiences coalesced around a central concept of destabilized identity, reflected in 5 interrelated themes: (1) yearning for an idealized past self; (2) shifting social roles; (3) existential uncertainty; (4) informational uncertainty; and (5) diverse emotional responses to identity conflict. Participants reported a loss of continuity with their premorbid selves, uncertainty about the future, and worries about sustaining cognitive and social functioning. This identity disruption was particularly distressing for younger adults navigating careers, relationships, and long-term life planning. Many expressed unmet support needs despite ongoing oncologic care. Conclusions: Disruption of personal identity emerged as a central feature of the experience of living with an IDH-mutant glioma. Supportive care that acknowledges and helps patients adapt to changes in their sense of self may improve overall psychosocial well-being and QOL.
- 20 April 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1741-1752
Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from a randomized controlled trial
Background: In a recent randomized controlled trial, caregivers of patients diagnosed with primary malignant brain tumors (PMBT) who received NeuroCARE—a 6-session, cognitive-behavioral, telehealth intervention—demonstrated improved anxiety and depression symptoms at 11 weeks post-randomization compared to caregivers assigned to usual care (UC). We explored whether these intervention effects were mediated by improvements in coping and self-efficacy. Methods: We examined data from caregivers of patients with PMBT randomized to receive either NeuroCARE or UC (N = 120). Participants completed assessments of anxiety and depression symptoms (Hospital Anxiety and Depression Scale), coping (Measure of Current Status), and self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline, 11 weeks, and 16 weeks. We conducted 4 simple mediation regression models using the Preacher & Hayes bootstrapping method to examine whether improvements in coping or self-efficacy from baseline to 11 weeks mediated intervention effects on 11-week anxiety or depression symptoms. Results: The sample (N = 120; Mage = 53 years) predominantly consisted of participants who self-identified as female (82.5%), White (91.7%), and spouses/partners (70.0%) caring for a patient with glioblastoma (84%). Improvements in 11-week anxiety symptoms in caregivers assigned to NeuroCARE were mediated by improved coping (indirect effect = −1.44, SE = 0.49, 95% CI [−2.50, −0.54]) and self-efficacy (indirect effect=−1.29, SE = 0.42, 95% CI [−2.16, −0.52]). Similarly, improvements in 11-week depression symptoms were mediated by improved coping (indirect effect=-1.43, SE = 0.38, 95% CI [−2.21, −0.74]) and self-efficacy (indirect effect = −0.95, SE = 0.32, 95% CI [−1.60, −0.36]). Conclusion: The NeuroCARE intervention improves mood by enhancing coping skills and improving caregivers’ self-efficacy in caregivers of patients with PMBT.
- 20 April 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1741-1752
Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from a randomized controlled trial
Background: In a recent randomized controlled trial, caregivers of patients diagnosed with primary malignant brain tumors (PMBT) who received NeuroCARE—a 6-session, cognitive-behavioral, telehealth intervention—demonstrated improved anxiety and depression symptoms at 11 weeks post-randomization compared to caregivers assigned to usual care (UC). We explored whether these intervention effects were mediated by improvements in coping and self-efficacy. Methods: We examined data from caregivers of patients with PMBT randomized to receive either NeuroCARE or UC (N = 120). Participants completed assessments of anxiety and depression symptoms (Hospital Anxiety and Depression Scale), coping (Measure of Current Status), and self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline, 11 weeks, and 16 weeks. We conducted 4 simple mediation regression models using the Preacher & Hayes bootstrapping method to examine whether improvements in coping or self-efficacy from baseline to 11 weeks mediated intervention effects on 11-week anxiety or depression symptoms. Results: The sample (N = 120; Mage = 53 years) predominantly consisted of participants who self-identified as female (82.5%), White (91.7%), and spouses/partners (70.0%) caring for a patient with glioblastoma (84%). Improvements in 11-week anxiety symptoms in caregivers assigned to NeuroCARE were mediated by improved coping (indirect effect = −1.44, SE = 0.49, 95% CI [−2.50, −0.54]) and self-efficacy (indirect effect=−1.29, SE = 0.42, 95% CI [−2.16, −0.52]). Similarly, improvements in 11-week depression symptoms were mediated by improved coping (indirect effect=-1.43, SE = 0.38, 95% CI [−2.21, −0.74]) and self-efficacy (indirect effect = −0.95, SE = 0.32, 95% CI [−1.60, −0.36]). Conclusion: The NeuroCARE intervention improves mood by enhancing coping skills and improving caregivers’ self-efficacy in caregivers of patients with PMBT.
- 20 December 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (36) , 4252-4262
NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors
PURPOSE: Caregivers of patients with primary malignant brain tumors (PMBT) experience significant psychological distress. We assessed the effect of a psychological intervention (NeuroCARE) on anxiety symptoms among PMBT caregivers. METHODS: We conducted a randomized trial of NeuroCARE versus usual care in PMBT caregivers with elevated anxiety (Generalized Anxiety Disorder-7 score ≥5) within 6 months of the patient's diagnosis. NeuroCARE was developed for PMBT caregivers and consists of six telehealth sessions with a behavioral health specialist. Participants completed surveys at baseline, 11-week (postintervention), and 16-week (1-month postintervention) time points. The primary outcome was 11-week anxiety symptoms (Hospital Anxiety and Depression Scale [HADS]-Anxiety Subscale). We also measured depression symptoms (HADS-Depression Subscale), quality of life (QOL; Caregiver QOL survey), caregiver burden (Caregiver Reaction Assessment), self-efficacy (Lewis Cancer Self-Efficacy Scale), coping (Measure of Current Status), and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist for DSM-5). We conducted analysis of covariance and linear mixed-effects regression analyses to examine intervention effects on study outcomes. RESULTS: We enrolled 120 caregivers (60/group) between October 2019 and June 2022; 105 were evaluable for the primary outcome. At 11 weeks, NeuroCARE participants reported significantly lower anxiety symptoms than usual care participants ( M , 8.87 v 10.69; P = .008). NeuroCARE caregivers also reported significantly lower depression symptoms ( M , 6.08 v 7.77; P = .004), and better self-efficacy ( M , 128.81 v 111.17; P < .001) and coping ( M , 32.25 v 25.65; P < .001) at 11 weeks. Study groups did not differ significantly in 11-week QOL, caregiver burden, or PTSD symptoms. In longitudinal analyses, intervention effects on depression symptoms, self-efficacy, and coping were sustained. CONCLUSION: A novel, population-specific psychological intervention led to improved anxiety and depression symptoms, self-efficacy, and coping among PMBT caregivers.
- 20 December 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (36) , 4252-4262
NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors
PURPOSE: Caregivers of patients with primary malignant brain tumors (PMBT) experience significant psychological distress. We assessed the effect of a psychological intervention (NeuroCARE) on anxiety symptoms among PMBT caregivers. METHODS: We conducted a randomized trial of NeuroCARE versus usual care in PMBT caregivers with elevated anxiety (Generalized Anxiety Disorder-7 score ≥5) within 6 months of the patient's diagnosis. NeuroCARE was developed for PMBT caregivers and consists of six telehealth sessions with a behavioral health specialist. Participants completed surveys at baseline, 11-week (postintervention), and 16-week (1-month postintervention) time points. The primary outcome was 11-week anxiety symptoms (Hospital Anxiety and Depression Scale [HADS]-Anxiety Subscale). We also measured depression symptoms (HADS-Depression Subscale), quality of life (QOL; Caregiver QOL survey), caregiver burden (Caregiver Reaction Assessment), self-efficacy (Lewis Cancer Self-Efficacy Scale), coping (Measure of Current Status), and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist for DSM-5). We conducted analysis of covariance and linear mixed-effects regression analyses to examine intervention effects on study outcomes. RESULTS: We enrolled 120 caregivers (60/group) between October 2019 and June 2022; 105 were evaluable for the primary outcome. At 11 weeks, NeuroCARE participants reported significantly lower anxiety symptoms than usual care participants ( M , 8.87 v 10.69; P = .008). NeuroCARE caregivers also reported significantly lower depression symptoms ( M , 6.08 v 7.77; P = .004), and better self-efficacy ( M , 128.81 v 111.17; P < .001) and coping ( M , 32.25 v 25.65; P < .001) at 11 weeks. Study groups did not differ significantly in 11-week QOL, caregiver burden, or PTSD symptoms. In longitudinal analyses, intervention effects on depression symptoms, self-efficacy, and coping were sustained. CONCLUSION: A novel, population-specific psychological intervention led to improved anxiety and depression symptoms, self-efficacy, and coping among PMBT caregivers.
- 1 December 2023
- Published by Wolters Kluwer Health in Continuum
- Vol. 29 (6) , 1752-1778
Skull Base Tumors
Esthesioneuroblastomas, and paragangliomas. Latest Developments Skull base tumors pose a management challenge given their complex location and, as a result, the tumors and treatment can result in significant morbidity. In most cases, surgery, radiation therapy, or both yield high rates of disease control, but the use of these therapies may be limited by the surgical accessibility of these tumors and their proximity to critical structures. The World Health Organization classification of pituitary neuroendocrine tumors was updated in 2022. Scientific advances have led to an enhanced understanding of the genetic drivers of many types of skull base tumors and have revealed several potentially targetable genetic alterations. This information is being leveraged in the design of ongoing clinical trials, with the hope of rendering these challenging tumors treatable through less invasive and morbid measures. Essential Points Tumors involving the skull base are heterogeneous and may arise from bony structures, cranial nerves, the meninges, the sinonasal tract, the pituitary gland, or embryonic tissues. Treatment often requires a multidisciplinary approach, with participation from radiation oncologists, medical oncologists, neuro-oncologists, and surgical specialists, including neurosurgeons, otolaryngologists, and head and neck surgeons. Treatment has largely centered around surgical resection, when feasible, and the use of first-line or salvage radiation therapy, with chemotherapy, targeted therapy, or both considered in selected settings. Our growing understanding of the molecular drivers of these diseases may facilitate future expansion of pharmacologic options to treat skull base tumors....
- 1 December 2023
- Published by Wolters Kluwer Health in Continuum
- Vol. 29 (6) , 1752-1778
Skull Base Tumors
Esthesioneuroblastomas, and paragangliomas. Latest Developments Skull base tumors pose a management challenge given their complex location and, as a result, the tumors and treatment can result in significant morbidity. In most cases, surgery, radiation therapy, or both yield high rates of disease control, but the use of these therapies may be limited by the surgical accessibility of these tumors and their proximity to critical structures. The World Health Organization classification of pituitary neuroendocrine tumors was updated in 2022. Scientific advances have led to an enhanced understanding of the genetic drivers of many types of skull base tumors and have revealed several potentially targetable genetic alterations. This information is being leveraged in the design of ongoing clinical trials, with the hope of rendering these challenging tumors treatable through less invasive and morbid measures. Essential Points Tumors involving the skull base are heterogeneous and may arise from bony structures, cranial nerves, the meninges, the sinonasal tract, the pituitary gland, or embryonic tissues. Treatment often requires a multidisciplinary approach, with participation from radiation oncologists, medical oncologists, neuro-oncologists, and surgical specialists, including neurosurgeons, otolaryngologists, and head and neck surgeons. Treatment has largely centered around surgical resection, when feasible, and the use of first-line or salvage radiation therapy, with chemotherapy, targeted therapy, or both considered in selected settings. Our growing understanding of the molecular drivers of these diseases may facilitate future expansion of pharmacologic options to treat skull base tumors....
- Open Access
Study protocol for NeuroCARE: a randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours
Introduction Caregivers of patients with primary malignant brain tumours experience substantial psychological distress while caring for someone with a progressive, life-limiting neurological illness. However, there are few interventions aimed at addressing the psychosocial needs of this population. We developed and are testing a population-specific, evidence-based, telehealth intervention (NeuroCARE) to reduce anxiety symptoms and improve psychosocial functioning in this caregiver population. Methods and analysis This study is a non-blinded, randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours receiving care at the Massachusetts General Hospital Cancer Center or Dana-Farber Cancer Institute. We will enrol 120 caregivers who screen positive for heightened anxiety. Participants will be randomised 1:1 to the NeuroCARE intervention or a usual care control condition. Caregivers assigned to NeuroCARE will complete six individual telehealth sessions with a trained behavioural health specialist over 12 weeks. Caregivers randomised to the control condition will receive usual care, including possible referral to social work or other appropriate resources. Participants will complete self-report questionnaires at baseline and 11 weeks and 16 weeks postrandomisation. The primary outcome is anxiety symptoms at 11 weeks among NeuroCARE participants, compared with usual care. Secondary outcomes include caregiver-reported depressive symptoms, quality of life, caregiver burden, caregiving self-efficacy, perceived coping skills and post-traumatic stress disorder symptoms. We also will explore potential mediators of the NeuroCARE effect on caregiver anxiety symptoms. Ethics and dissemination The study is funded by a Career Development Award from Conquer Cancer, the American Society of Clinical Oncology Foundation (award number 2019CDA-7743456038) and approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #19-250 V.10.1). The study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for non-pharmacological trials. Results will be presented at scientific meetings and in peer-reviewed journals. Trial registration number NCT04109209
Open AccessStudy protocol for NeuroCARE: a randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours
Introduction Caregivers of patients with primary malignant brain tumours experience substantial psychological distress while caring for someone with a progressive, life-limiting neurological illness. However, there are few interventions aimed at addressing the psychosocial needs of this population. We developed and are testing a population-specific, evidence-based, telehealth intervention (NeuroCARE) to reduce anxiety symptoms and improve psychosocial functioning in this caregiver population. Methods and analysis This study is a non-blinded, randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours receiving care at the Massachusetts General Hospital Cancer Center or Dana-Farber Cancer Institute. We will enrol 120 caregivers who screen positive for heightened anxiety. Participants will be randomised 1:1 to the NeuroCARE intervention or a usual care control condition. Caregivers assigned to NeuroCARE will complete six individual telehealth sessions with a trained behavioural health specialist over 12 weeks. Caregivers randomised to the control condition will receive usual care, including possible referral to social work or other appropriate resources. Participants will complete self-report questionnaires at baseline and 11 weeks and 16 weeks postrandomisation. The primary outcome is anxiety symptoms at 11 weeks among NeuroCARE participants, compared with usual care. Secondary outcomes include caregiver-reported depressive symptoms, quality of life, caregiver burden, caregiving self-efficacy, perceived coping skills and post-traumatic stress disorder symptoms. We also will explore potential mediators of the NeuroCARE effect on caregiver anxiety symptoms. Ethics and dissemination The study is funded by a Career Development Award from Conquer Cancer, the American Society of Clinical Oncology Foundation (award number 2019CDA-7743456038) and approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #19-250 V.10.1). The study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for non-pharmacological trials. Results will be presented at scientific meetings and in peer-reviewed journals. Trial registration number NCT04109209